Skip to main content
. 2024 Feb 6;16(4):680. doi: 10.3390/cancers16040680

Figure 5.

Figure 5

A summarized illustration of various molecular mechanisms and the scope of potential combinatorial avenues that can alleviate topo-active drug resistance in cancer cells. DNA repair protein (DRP) inhibitors. ATP-binding cassette (ABC) transporter. Epithelial–mesenchymal transition (EMT). Glutathione (GSH). Histone deacetylase (HDAC). Cancer stem cells (CSCs).